• Education

    University of Bern, 1989

  • Residencies

    Indiana University School of Medicine, Internal Medicine, 1996

  • Fellowships

    Memorial Sloan-Kettering Cancer Center, Hematology-Oncology, 2000

  • Academic Title

    Professor

  • Languages

    French

    German

    Italian

Clinics I work with

Breast Care Center

Berkeley Outpatient Center

3100 San Pablo Ave., Suite 430
Berkeley, CA 94702

Hereditary Cancer Clinic

Bakar Precision Cancer Medicine Building

See both of our San Francisco locations.

My reviews

4.8

Overall Experience
103 Reviews
Explained things in a way that was easy to understand
103 Reviews
Did the doctor pay attention to your concerns
103 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
99 Reviews
Knew the important information about your medical history
101 Reviews
The provider showed respect for what you had to say
102 Reviews
The provider spent enough time with me
102 Reviews
Decorative Caduceus

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects...

Treatment-emergent adverse events will be a primary outcome measure for the following groups: Phase 1 Dose Exploration Part 1 monotherapy Phase 1 Dose Expansion Part 2 monotherapy Phase 1 combination arm with AMG 510 and anti P...

Recruiting

Decorative Caduceus

Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in ...

A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related

Recruiting

Decorative Caduceus

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab.

Recruiting

Decorative Caduceus

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values or vital signs for RMC-5552 monotherapy

Recruiting

Decorative Caduceus

9-ING-41 in Patients With Advanced Cancers

The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint.

Recruiting

Decorative Caduceus

AO-176 in Multiple Solid Tumor Malignancies

Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities.

Recruiting

Decorative Caduceus

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Sol...

Identify nature and frequency of dose limiting toxicities

Recruiting

Decorative Caduceus

Study of ORIC-101 in Combination With Anticancer Therapy

RP2D as determined by 3+3 dose escalation design

Recruiting

Decorative Caduceus

A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in H...

Best overall response rate as assessed by the investigator by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in patients with advanced prostate cancer).

Recruiting

Share